ArticleArthroplasty today2026
Inflammatory Bowel Disease and Periprosthetic Joint Infection Following Total Joint Arthroplasty: Crohn's Disease and Ulcerative Colitis Associated With Varying Risk.
Article in Arthroplasty today, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The risk of periprosthetic joint infection (PJI) in patients with inflammatory bowel disease (IBD) who undergo total joint arthroplasty (TJA) remains unclear as reports in the literature are inconclusive. This study sought to clarify the relationship between IBD and PJI risk after TJA. Methods: An all-payer claims database was used to identify patients who underwent primary elective TJA between 2016 and 2023. Patients who had a diagnosis of Crohn's disease (CD) or ulcerative colitis (UC) were identified. Propensity score matching (1:7) was performed for the UC, CD, and aggregate IBD cohorts based on age, sex, and comorbidities. Ninety-day PJI risk was assessed using multivariable regression. Results: In total, 10,040 patients with IBD were identified and matched to 70,203 controls. Separately, 5474 CD patients were matched to 38,230 controls, and 4555 UC patients were matched to 31,865 controls. PJI rates were similar between the IBD and control cohorts (0.71% vs 0.61%; Discussion: CD is independently associated with increased PJI risk following TJA, while UC is not. This distinction may account for inconsistencies in the literature evaluating IBD as a risk factor for PJI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.